Our findings demonstrated that TGQZD is a useful and effective therapeutic agent for treating NAFLD via promotion of CGI-58 to inhibit the expression of ROS-induced NLRP3 inflammasome. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.